
The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
To own Azenta, you need to believe its sample management and multiomics services can translate steady life sciences demand into sustainable, profitable growth despite recent net losses. Inclusion in the Russell 2000 Defensive and Value Defensive indices may increase visibility and liquidity, but it does not fundamentally change the near term earnings pressure or the key risk that higher spending and soft spots in core services keep margins under strain.
The most relevant recent announcement here is Azenta’s May 2026 guidance, which points to full year revenue of US$603 million to US$621 million. That outlook underpins the current catalyst of gradually improving fundamentals, but the sharp year to date net loss and ongoing investments mean investors still need to watch how efficiently new revenue converts into earnings as any index driven inflows come through.
Yet behind the defensive index label, investors should still be aware of the risk that continued losses and elevated spending could...
Read the full narrative on Azenta (it's free!)
Azenta's narrative projects $684.6 million revenue and $37.8 million earnings by 2029.
Uncover how Azenta's forecasts yield a $26.20 fair value, in line with its current price.
The lowest estimate analysts took a tougher view, assuming revenue of about US$704.6 million and earnings of US$34.3 million by 2029, reminding you that index inclusion might not fully offset concerns about margin pressure and execution, and that views on Azenta’s potential can differ widely.
Explore 2 other fair value estimates on Azenta - why the stock might be worth just $26.20!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com